The carrying values of the Company's investments, by accounting category, were as follows (in millions):


Date	Equity Method (1)		Fair Value (2)		Measurement Alternative (3)		Total
June 30, 2026	$	0.9	$	0.4	$	0.9	$	2.2
December 31, 2025	$	0.9	$	—	$	0.9	$	1.8

(1) The Company's equity method investments were comprised of MediBeacon and Scaled Cell as of both June 30, 2026 and December 31, 2025.

(2) The Company's fair value investments in common stock are comprised of marketable equity securities in a publicly traded company that were purchased in April 2026 and sold subsequent to quarter end in July 2026.

(3) The Company's measurement alternative method investment was comprised of Triple Ring as of both June 30, 2026 and December 31, 2025.

The Company's recognized share of net losses from its equity method investments was zero and $5.9 million for the six months ended June 30, 2026 and 2025, respectively.

Pansend accounts for its preferred stock investment in MediBeacon under the equity method of accounting, inclusive of any fixed maturity securities (notes) issued by MediBeacon to Pansend.

On January 17, 2025, MediBeacon received approval from the U.S. Food and Drug Administration ("FDA") for its Transdermal GFR Measurement System ("TGFR"). Pursuant to the terms of MediBeacon's convertible notes, upon the FDA approval, Pansend's convertible notes of $11.4 million and the related accrued interest of $1.5 million, together totaling $12.9 million, were converted into Series 3 Preferred Stock. In addition, pursuant to its amended commercial partnership with Huadong and, as a result of FDA approval, a $7.5 million milestone payment from Huadong Medicine Co. Ltd ("Huadong"), a publicly traded company on the Shenzhen Stock Exchange, to MediBeacon for MediBeacon preferred stock was received in the first quarter of 2025. As a result of these transactions, Pansend's ownership in MediBeacon decreased slightly and Pansend recognized a step-up gain of $4.4 million which is reflected in Other income, net in the Condensed Consolidated Statements of Operations for the six months ended June 30, 2025, which increased Pansend's carrying amount of its investment in MediBeacon. Concurrently, Pansend recognized equity method losses of $5.9 million, driven by the $4.4 million step-up gain and $1.5 million of interest from the conversion of the convertible notes, which were previously unrecognized because Pansend's carrying amount of its investment in MediBeacon had been previously reduced to zero.

MediBeacon's total outstanding principal amount of the note due to Pansend was $0.5 million as of both June 30, 2026 and December 31, 2025. Interest income earned by Pansend from the MediBeacon notes totaled $30 thousand and $0.1 million for the six months ended June 30, 2026 and 2025, respectively. The related accrued interest receivable was $0.4 million, as of both June 30, 2026 and December 31, 2025. The $0.5 million note had a maturity date of July 5, 2026. Refer to Note 22. Subsequent Events for additional information.

As of June 30, 2026, Pansend's carrying amount of its investment in MediBeacon remained at zero, inclusive of the $0.5 million in secured promissory notes which has been offset against recognized equity method losses, and Pansend has cumulative unrecognized equity method losses relating to MediBeacon of $22.6 million.

Marketable Securities

In April 2026, the Company purchased common shares in the open market of a publicly traded company for approximately $0.5 million. These securities are remeasured at fair value each reporting period using the externally quoted market prices, Fair Value Level 1 inputs. For both the three and six months ended June 30, 2026, unrealized fair value losses of $0.1 million, related to these securities, were included in Other income, net in the Condensed Consolidated Financial Statements. Subsequent to quarter end, in July 2026, the Company sold all of these shares for aggregate proceeds of $0.6 million.

In October 2024, the Company purchased common shares in the open market of a publicly traded company for approximately $2.0 million, and in March 2025, the Company purchased common shares in the open market of another publicly traded company for $0.3 million. In July 2025, all of these shares were sold for aggregate proceeds of $2.9 million. Prior to their disposal, these securities were remeasured at fair value each reporting period using the externally quoted market prices, Fair Value Level 1 inputs. For the three months and six months ended June 30, 2025, unrealized fair value gains of $0.3 million and $0.5 million, respectively, related to these securities were included in Other income, net in the Condensed Consolidated Financial Statements.